Jardiance (Cardinal Health)
Welcome to the PulseAid listing for the Jardiance drug offered from Cardinal Health. This Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Cardinal Health |
| NON-PROPRIETARY NAME: | Empagliflozin |
| SUBSTANCE NAME: | EMPAGLIFLOZIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2014-08-01 |
| END MARKETING DATE: | 0000-00-00 |
Jardiance HUMAN PRESCRIPTION DRUG Details:
| Item Description | Jardiance from Cardinal Health |
| LABELER NAME: | Cardinal Health |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 10(mg/1) |
| START MARKETING DATE: | 2014-08-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 55154-0411_5777b8a8-ada6-4950-8548-43a1de11f075 |
| PRODUCT NDC: | 55154-0411 |
| APPLICATION NUMBER: | NDA204629 |
Other EMPAGLIFLOZIN Pharmaceutical Manufacturers / Labelers:
